Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

9.930 -0.270 (-2.65%)
Streaming Delayed Price Updated: 11:11 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 195,094
Open 9.980
Bid (Size) 9.910 (1)
Ask (Size) 9.990 (2)
Prev. Close 10.20
Today's Range 9.717 - 10.15
52wk Range 3.300 - 11.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga

Performance

YTD
+33.8%
+33.8%
1 Month
+65.5%
+65.5%
3 Month
+59.9%
+59.9%
6 Month
+133.1%
+133.1%
1 Year
+5.1%
+5.1%

More News

Read More
Immatics Appoints Venkat Ramanan as Chief Financial Officer
From https://immatics.com/
Via GlobeNewswire
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Immatics Announces Second Quarter 2025 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
From https://immatics.com/
Via GlobeNewswire
Immatics Announces First Quarter 2025 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Full Year 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Pricing of $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immatics Announces Proposed $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
From https://immatics.com/
Via GlobeNewswire
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
Via Talk Markets
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
From https://immatics.com/
Via GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Immatics Announces Second Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
From https://immatics.com/
Via GlobeNewswire

Frequently Asked Questions

Is Immatics N.V. - Ordinary Shares publicly traded?
Yes, Immatics N.V. - Ordinary Shares is publicly traded.
What exchange does Immatics N.V. - Ordinary Shares trade on?
Immatics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Immatics N.V. - Ordinary Shares?
The ticker symbol for Immatics N.V. - Ordinary Shares is IMTX on the Nasdaq Stock Market
What is the current price of Immatics N.V. - Ordinary Shares?
The current price of Immatics N.V. - Ordinary Shares is 9.930
When was Immatics N.V. - Ordinary Shares last traded?
The last trade of Immatics N.V. - Ordinary Shares was at 10/17/25 11:11 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.